Early development of sunitinib in hepatocellular carcinoma

References

• Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin.55, 74–108 (2005).
   PubMed Web of Science ®Google Scholar
• McGlynn KA, London WT. Epidemiology and natural history of hepatocellular carcinoma. Best Pract. Res. Clin. Gastroenterol.19, 3–23 (2005).
   PubMed Web of Science ®Google Scholar
• El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology132, 2557–2576 (2007).
   PubMed Web of Science ®Google Scholar
• Yu MC, Yuan JM. Environmental factors and risk for hepatocellular carcinoma. Gastroenterology127, S72–S78 (2004).
   PubMed Web of Science ®Google Scholar
• Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl.9, 331–338 (2003).
   PubMed Web of Science ®Google Scholar
• Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet362, 1907–1917 (2003).
   PubMed Web of Science ®Google Scholar
• Grieco A, Pompili M, Caminiti G et al. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. Gut54, 411–418 (2005).
   PubMed Web of Science ®Google Scholar
• Bruix J, Sherman M, Llovet JM et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona–2000 EASL conference. European Association for the Study of the Liver. J. Hepatol.35, 421–430 (2001).
   PubMed Web of Science ®Google Scholar
• Zhu AX. Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be? Oncologist11, 790–800 (2006).
   PubMed Web of Science ®Google Scholar
• Wang BL, Chen XP, Zhai SP, Chen DF. Clinical significance of mrp gene in primary hepatocellular carcinoma. Hepatobiliary Pancreat. Dis. Int.2, 397–403 (2003).
   Google Scholar
• Yeo W, Mok TS, Zee B et al. A randomized Phase III study of doxorubicin versus cisplatin/interferon α-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J. Natl Cancer Inst.97, 1532–1538 (2005).
   PubMed Web of Science ®Google Scholar
• Lee J, Park JO, Kim WS et al. Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma. Cancer Chemother. Pharmacol.54, 385–390 (2004).
   Google Scholar
• Taïeb J, Bonyhay L, Golli L et al. Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules. Cancer98, 2664–2670 (2003).
   PubMed Web of Science ®Google Scholar
• Ikeda M, Okusaka T, Ueno H, Takezako Y, Morizane C. A Phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma. Cancer103, 756–762 (2005).
   Google Scholar
• Lopez PM, Patel P, Uva P, Villanueva A, Llovet JM. Current management of liver cancer. Eur. J. Cancer Suppl.5, 444–446 (2007).
   Google Scholar
• Folkman J. Fundamental concepts of the angiogenic process. Curr. Mol. Med.3, 643–651 (2003).
   PubMed Web of Science ®Google Scholar
• Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol.23, 1011–1027 (2005).
   PubMed Web of Science ®Google Scholar
• Wada H, Nagano H, Yamamoto H et al. Expression pattern of angiogenic factors and prognosis after hepatic resection in hepatocellular carcinoma: importance of angiopoietin-2 and hypoxia-induced factor-1α. Liver Int.26, 414–423 (2006).
   PubMed Web of Science ®Google Scholar
• Yang LY, Lu WQ, Huang GW, Wang W. Correlation between CD105 expression and postoperative recurrence and metastasis of hepatocellular carcinoma. BMC Cancer6, 110 (2006).
   PubMedGoogle Scholar
• Tugues S, Fernandez-Varo G, Muñoz-Luque J et al. Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. Hepatology46, 1919–1926 (2007).
   PubMed Web of Science ®Google Scholar
• Zhang ZL, Liu ZS, Sun Q. Expression of angiopoietins, Tie2 and vascular endothelial growth factor in angiogenesis and progression of hepatocellular carcinoma. World J. Gastroenterol.12, 4241–4245 (2006).
   PubMed Web of Science ®Google Scholar
• Yao DF, Wu XH, Zhu Y et al. Quantitative analysis of vascular endothelial growth factor, microvascular density and their clinicopathologic features in human hepatocellular carcinoma. Hepatobiliary Pancreat. Dis. Int.4, 220–226 (2005).
   PubMedGoogle Scholar
• Amaoka N, Saio M, Nonaka K et al. Expression of vascular endothelial growth factor receptors is closely related to the histological grade of hepatocellular carcinoma. Oncol. Rep.16, 3–10 (2006).
   PubMed Web of Science ®Google Scholar
• Poon RT, Ho JW, Tong CS, Lau C, Ng IO, Fan ST. Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br. J. Surg.91, 1354–1360 (2004).
   PubMed Web of Science ®Google Scholar
• Chao Y, Li CP, Chau GY et al. Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery. Ann. Surg. Oncol.10, 355–362 (2003).
   PubMed Web of Science ®Google Scholar
• Pietras K, Hanahan D. A multitargeted, metronomic, and maximum-tolerated dose “chemo-switch” regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J. Clin. Oncol.23, 939–952 (2005).
   PubMed Web of Science ®Google Scholar
• Stock P, Monga D, Tan X, Micsenyi A, Loizos N, Monga SP. Platelet-derived growth factor receptor-α: a novel therapeutic target in human hepatocellular cancer. Mol. Cancer Ther.6, 1932–1941 (2007).
   PubMed Web of Science ®Google Scholar
• Zhang T, Sun HC, Xu Y et al. Overexpression of platelet-derived growth factor receptor-α in endothelial cells of hepatocellular carcinoma associated with high metastatic potential. Clin. Cancer Res.11, 8557–8563 (2005).
   PubMed Web of Science ®Google Scholar
• Gollob JA, Wilhelm S, Carter C, Kelley SL. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin. Oncol.33, 392–406 (2006).
   PubMed Web of Science ®Google Scholar
• Avila MA, Berasain C, Sangro B, Prieto J. New therapies for hepatocellular carcinoma. Oncogene25, 3866–3884 (2006).
   PubMed Web of Science ®Google Scholar
• Stöckl L, Berting A, Malkowski B et al. Integrity of c-Raf-1/MEK signal transduction cascade is essential for hepatitis B virus gene expression. Oncogene22, 2604–2610 (2003).
   Google Scholar
• Zhu AX. Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma. Cancer112, 250–259 (2008).
   PubMed Web of Science ®Google Scholar
• Nexavar® (sorafenib) tablets oral [package insert]. Bayer Pharmaceuticals, West Haven, CT, USA (2007).
   Google Scholar
• Wilhelm SM, Carter C, Tang L et al. BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res.64, 7099–7109 (2004).
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Schwartz L, Ricci S et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J. Clin. Oncol.24, 4293–4300 (2006).
   PubMed Web of Science ®Google Scholar
• Llovet J, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med.359, 378–390 (2008).
   PubMed Web of Science ®Google Scholar
• Cheng A, Kang Y, Chen Z et al. Randomized Phase III trial of sorafenib versus placebo in Asian patients with advanced hepatocellular carcinoma. J. Clin. Oncol.(Meeting Abstracts)26 (2008) (Abstract 4509).
   Google Scholar
• Chow LQM, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J. Clin. Oncol.25, 884–896 (2007).
   PubMed Web of Science ®Google Scholar
• Faivre S, Delbaldo C, Vera K et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J. Clin. Oncol.24, 25–35 (2006).
   PubMed Web of Science ®Google Scholar
• Faivre S, Demetri G, Sargent W et al. Molecular basis for sunitinib efficacy and future clinical development. Nat. Rev. Drug Discov.6, 734–745 (2007).
   PubMed Web of Science ®Google Scholar
• Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM. SU11248 inhibits KIT and platelet-derived growth factor receptor-β in preclinical models of human small cell lung cancer. Mol. Cancer Ther.2, 471–478 (2003).
   PubMed Web of Science ®Google Scholar
• Mendel DB, Laird AD, Xin X et al.In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res.9, 327–337 (2003).
   PubMed Web of Science ®Google Scholar
• Murray LJ, Abrams TJ, Long KR et al. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin. Exp. Metastasis20, 757–766 (2003).
   PubMed Web of Science ®Google Scholar
• O’Farrell AM, Abrams TJ, Yuen HA et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood101, 3597–3605 (2003).
   PubMed Web of Science ®Google Scholar
• Kim DW, Jo YS, Jung HS et al. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J. Clin. Endocrinol. Metab.91, 4070–4076 (2006).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon-α in metastatic renal-cell carcinoma. N. Engl. J. Med.356, 115–124 (2007).
   PubMed Web of Science ®Google Scholar
• Demetri GD, van Oosterom AT, Garrett CR et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet368, 1329–1338 (2006).
   PubMed Web of Science ®Google Scholar
• Osusky KL, Hallahan DE, Fu A, Ye F, Shyr Y, Geng L. The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels. Angiogenesis7, 225–233 (2004).
   PubMedGoogle Scholar
• Potapova O, Laird AD, Nannini MA et al. Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248. Mol. Cancer Ther.5, 1280–1289 (2006).
   PubMed Web of Science ®Google Scholar
• Marzola P, Degrassi A, Calderan L et al. Early antiangiogenic activity of SU11248 evaluated in vivo by dynamic contrast-enhanced magnetic resonance imaging in an experimental model of colon carcinoma. Clin. Cancer Res.11, 5827–5832 (2005).
   PubMed Web of Science ®Google Scholar
• Zhu A, Sahani D, di Tomaso E et al. Efficacy, safety, and changes in blood markers following sunitinib monotherapy in patients with advanced hepatocellular carcinoma: experience from a multidisciplinary Phase II study. Presented at: 99th AACR Annual Meeting. San Diego, CA, USA, 12–16 April 2008.
   Google Scholar
• Faivre S, DePrimo S, Cheng AL et al. Correlation of outcome and tumour imaging parameters with circulating biomarkers of sunitinib malate in patients with unresectable hepatocellular carcinoma. Presented at: 33rd ESMO Congress. Stockholm, Sweden, 12–16 September 2008.
   Google Scholar
• Wood LS. Managing the side effects of sorafenib and sunitinib. Community Oncol.3, 558–562 (2006).
   Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl Cancer Inst.92, 205–216 (2000).
   PubMed Web of Science ®Google Scholar
• Choi H, Charnsangavej C, Faria SC et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J. Clin. Oncol.25, 1753–1759 (2007).
   PubMed Web of Science ®Google Scholar
• Benjamin RS, Choi H, Macapinlac HA et al. We should desist using RECIST, at least in GIST. J. Clin. Oncol.25, 1760–1764 (2007).
   PubMed Web of Science ®Google Scholar
• Siegel AB, Cohen EI, Ocean A et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J. Clin. Oncol.26, 2992–2998 (2008).
   PubMed Web of Science ®Google Scholar
• Zhu AX, Blaszkowsky LS, Ryan DP et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J. Clin. Oncol.24, 1898–1903 (2006).
   PubMed Web of Science ®Google Scholar
• Christensen JG. A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities. Ann. Oncol.18(Suppl. 10), 3–10 (2007).
   Google Scholar
• Wilhelm S, Carter C, Lynch M et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat. Rev. Drug Discov.5, 835–844 (2006).
   PubMed Web of Science ®Google Scholar